Analysis details immune modulation by TGF-β2 in cholestatic liver disease, revealing effects on inflammatory cells.
Primary sclerosing cholangitis (PSC) and the MDR2KO mouse model are characterized by chronic cholestatic liver inflammation and fibrosis. Silencing of transforming growth factor-beta 2 (TGF-β2), a known driver of fibrosis, has shown a decrease of CD45+cells, an increase of F4/80+cells and CD8+T cells, and recruitment of eosinophils in the livers of MDR2KO mice, implicating a key immunomodulatory role in this context. This project aims to delineate the specific mechanisms involved upon TGF-β2 treatment in regulating immune cell behavior in biliary liver disease.
No takes yet. Share an insight, caveat, or question.
Bötsch et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: